President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover weight loss drugs, ...

Jamie Mafdali of South Florida was hit with a cancer double-whammy three years ago. Shortly after her mother began treatment ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

BUFFALO, N.Y. — In January, Nicole Albanese, PharmD, clinical associate professor of pharmacy practice in the University at ...

Health and Human Services Secretary Robert F. Kennedy Jr. has been critical of the drugs, instead placing a focus on ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden administration for Medicare coverage of weight-loss drugs such as Novo ...

Donald Trump, at 78, is aggressively pursuing his second term, marked by significant policy changes and a noticeable physical ...

The average annual cost per patient for a GLP-1 drug is $12,000, according to a Peterson-KFF tracker. About half of Americans “strongly” or “somewhat” favor having Medicare and Medicaid cover ...

The Centers for Medicare & Medicaid Services on Friday rejected a Biden administration proposal to expand Medicare coverage of weight-loss drugs such as Eli Lilly's Zepbound and Novo Nordisk's ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...